Juno Therapeutics, Inc. (JUNO) Price Target Raised to $61.00 at Raymond James Financial, Inc.
Juno Therapeutics, Inc. (NASDAQ:JUNO) had its price objective boosted by Raymond James Financial, Inc. from $45.00 to $61.00 in a research report issued to clients and investors on Friday. The brokerage currently has an “outperform” rating on the biopharmaceutical company’s stock. Raymond James Financial, Inc.’s price target would suggest a potential upside of 4.31% from the stock’s current price.
Several other research analysts have also recently commented on the company. Cowen and Company reaffirmed a “buy” rating on shares of Juno Therapeutics in a research report on Friday. Maxim Group reissued a “buy” rating and set a $56.00 price objective on shares of Juno Therapeutics in a report on Thursday. Leerink Swann reissued an “in-line” rating and set a $56.00 price objective (up from $34.00) on shares of Juno Therapeutics in a report on Thursday. Wedbush reissued an “outperform” rating and set a $64.00 price objective (up from $42.00) on shares of Juno Therapeutics in a report on Thursday. Finally, SunTrust Banks, Inc. raised Juno Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $44.20.
Shares of Juno Therapeutics (NASDAQ JUNO) traded up $10.17 during mid-day trading on Friday, reaching $58.48. The company had a trading volume of 5,482,719 shares, compared to its average volume of 2,320,000. Juno Therapeutics has a 52-week low of $17.52 and a 52-week high of $61.59. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 5.08.
Juno Therapeutics (NASDAQ:JUNO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. Juno Therapeutics’s quarterly revenue was up 115.4% compared to the same quarter last year. During the same period last year, the business earned ($0.57) earnings per share. sell-side analysts predict that Juno Therapeutics will post -3.53 earnings per share for the current fiscal year.
In other news, General Counsel Bernard J. Cassidy sold 28,000 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $44.92, for a total value of $1,257,760.00. Following the completion of the sale, the general counsel now directly owns 55,970 shares in the company, valued at $2,514,172.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard Klausner sold 12,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $30.34, for a total value of $364,080.00. Following the completion of the sale, the director now owns 788,985 shares of the company’s stock, valued at $23,937,804.90. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 91,670 shares of company stock valued at $3,917,857. 15.26% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in the company. Teachers Advisors LLC increased its position in Juno Therapeutics by 15.4% in the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after purchasing an additional 9,890 shares during the period. QS Investors LLC acquired a new stake in Juno Therapeutics in the second quarter worth about $135,000. State Street Corp increased its position in Juno Therapeutics by 7.4% in the second quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after purchasing an additional 222,754 shares during the period. Wasatch Advisors Inc. acquired a new stake in Juno Therapeutics in the second quarter worth about $19,787,000. Finally, Marshall Wace LLP acquired a new stake in Juno Therapeutics in the second quarter worth about $1,071,000. Institutional investors own 67.18% of the company’s stock.
Juno Therapeutics Company Profile
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.